NASDAQ:UBX

Unity Biotechnology Stock Forecast, Price & News

Followed 133 Times

$6.92

-0.21 (-2.95 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$6.81

Now: $6.92▼

$7.39

50-Day Range

$5.14

MA: $5.85▼

$7.13

52-Week Range

$2.72

Now: $6.92▼

$15.44

Volume1.18 million shs

Average Volume987,856 shs

Market Capitalization$366.16 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.15

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.

MarketRank^™

Overall MarketRank^™

1.20 out of 5 stars

Medical Sector

720th out of 1,556 stocks

Biotechnology Industry

11th out of 80 stocks

1.1 Analyst's Opinion

Consensus Rating
Unity Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.40, Unity Biotechnology has a forecasted downside of 36.4% from its current price of $6.92.
Amount of Analyst Coverage
Unity Biotechnology has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
Unity Biotechnology has received 143 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Unity Biotechnology has received 137 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Unity Biotechnology has received 51.07% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote “Outperform” if you believe UBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Unity Biotechnology does not currently pay a dividend.
Dividend Growth
Unity Biotechnology does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Unity Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,908,000.00 in company stock.
Percentage Held by Insiders
37.30% of the stock of Unity Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.89% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Unity Biotechnology are expected to grow in the coming year, from ($1.75) to ($1.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Unity Biotechnology is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Unity Biotechnology is -3.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:UBX

Previous Symbol

CUSIPN/A

CIK1463361

Webwww.unitybiotechnology.com

Phone650 416 1192

Employees76

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares52,913,000

Market Cap$366.16 million

Next Earnings Date3/10/2021 (Estimated)

OptionableNot Optionable

$6.92

-0.21 (-2.95 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock price been impacted by COVID-19?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UBX shares have increased by 28.4% and is now trading at $6.92.
View which stocks have been most impacted by COVID-19.

Is Unity Biotechnology a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Unity Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UBX, but not buy additional shares or sell existing shares.
View analyst ratings for Unity Biotechnology or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Unity Biotechnology?

Wall Street analysts have given Unity Biotechnology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Unity Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Unity Biotechnology.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) announced its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.07.
View Unity Biotechnology's earnings history.

What price target have analysts set for UBX?

5 brokerages have issued twelve-month price targets for Unity Biotechnology's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Unity Biotechnology's stock price to reach $4.40 in the next twelve months. This suggests that the stock has a possible downside of 36.4%.
View analysts' price targets for Unity Biotechnology or view Wall Street analyst' top-rated stocks.

Who are some of Unity Biotechnology's key competitors?

Some companies that are related to Unity Biotechnology include Travere Therapeutics (TVTX), Concordia International Corp. (CXR.TO) (CXR), PureTech Health (PRTC), Sigilon Therapeutics (SGTX), Tarsus Pharmaceuticals (TARS), Oxford Biomedica plc (OXB.L) (OXB), Novacyt S.A. (NCYT.L) (NCYT), SQZ Biotechnologies (SQZ), Oncorus (ONCR), Inventiva (IVA), Biotest Aktiengesellschaft (BIO.F) (BIO), Spruce Biosciences (SPRB), Opthea (OPT), Aptose Biosciences (APS) and Ergomed plc (ERGO.L) (ERGO).
View all of UBX's competitors.

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:

Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
Dr. Anirvan Ghosh, CEO & Director (Age 56)
Dr. Jan M. van Deursen, Founder
Dr. Judith Campisi, Founder
Mr. Daohong Zhou M.D., Founder
Ms. Lynne Marie Sullivan, Chief Financial Officer (Age 54)
Mr. Douglas A. Rich, Sr. VP of Operations (Age 51)
Mr. Alexander Azoy, VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer (Age 44)
Dr. Daniel G. Marquess D.Phil, Chief Scientific Officer (Age 51)
Ms. Camille Landis, Sr. VP of Corp. Devel.

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $6.92.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $366.16 million. Unity Biotechnology employs 76 workers across the globe.

What is Unity Biotechnology's official website?

The official website for Unity Biotechnology is www.unitybiotechnology.com.

How can I contact Unity Biotechnology?

The company can be reached via phone at 650 416 1192.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here